Dr. David Josephy

My continuing working relationship with the scientists at EBPI has facilitated the development and commercialization of new engineered bacterial strains that carry out metabolic activation processes, making it possible to detect priority mutagens/ carcinogens with enhanced sensitivity and reliability.